|
Poster number |
Title |
Submitting author |
City and Country |
|
154 |
PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT |
Andrés Ferreri |
Milano, Italy |
|
155 |
Liquid-biopsy based genotyping of Primary Central Nervous System Lymphoma (PCNSL) |
Jan-Michel Heger |
Cologne, Germany |
|
156 |
SARS-CoV-2 INFECTION IN 50 PATIENTS WITH PRIMARY CNS LYMPHOMA: PRESENTATION, EFFECTS ON TUMOR TREATMENT AND OUTCOME IN A SERIES OF THE INTERNATIONAL PCNSL COLLABORATIVE GROUP |
Andrés Ferreri |
Milano, Italy |
|
157 |
Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Real World (RW) Outcomes of Post-Induction Therapy in the Modern Era |
Kevin David |
New Brunswick, NJ, USA |
|
158 |
Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (CNS-PTLD): A 20 years Retrospective Single Center Experience |
Noemie Lang* |
Toronto, Canada |
|
159 |
Phase Ib/II study of Lenalidomide, Rituximab, High-dose Methotrexate (R2-MTX) regimen, followed by lenalidomide maintenance in Newly Diagnosed Primary CNS Lymphoma |
Yan Zhang |
Beijing, China |
|
160 |
Use of methotrexate, whatever kidney function, with a simple algorithm, radically changes the prognosis of post-transplant CNS lymphomas |
Sylvain Choquet |
Paris, France |
|
161 |
Combination of rituximab-lenalidomide-ibrutinib in relapsed/refractory primary CNS lymphoma: a cohort study of the LOC network |
Caroline Houillier |
Paris, France |
|
162 |
CAR-T cell therapy in primary central nervous system lymphoma (PCNSL): the experience of the French network for oculo-cerebral lymphomas (LOC) |
Sylvain Choquet |
Paris, France |
|
163 |
Lenalidomide and rituximab regimen combined with intravitreal methotrexate followed by lenalidomide maintenance for primary vitreoretinal lymphoma: a prospective phase II study |
Yan Zhang |
Beijing, China |
|
164 |
RITUXIMAB-DOSE-ADJUSTED EPOCH (R-da-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES |
Theodoros Vassilakopoulos |
Athens, Greece |
|
165 |
Primary Mediastinal B-cell Lymphoma: Intensified regimens do not improve outcomes as compared to RCHOP in a resource-constrained setting |
Rodrigo Velasques |
São Paulo, Brazil |